Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have jointly patented acylsulfonamide histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
μ-Opioid receptor agonists have been described in a Miralogx LLC patent as potentially useful for anesthesia and sedation and the treatment of anxiety disorders, asthma, depression and pain.
In research conducted at West China Hospital of Sichuan University and Chengdu University of Traditional Chinese Medicine, coupling of the pan-FGFR inhibitor erdafitinib with a CRBN binder led to a new series of fibroblast growth factor receptor (FGFR) degraders, with compound [I] identified as the lead candidate.
Investigators at Nanjing Medical University and The University of Texas MD Anderson Cancer Center recently published data from their research that aimed to identify novel immunotherapy targets in triple-negative breast cancer (TNBC).
Metastasis is the leading cause of mortality in patients with small-cell lung cancer (SCLC), with limited therapeutic options available. SCLC is characterized by a high proliferation rate, early metastasis and poor prognosis.
CSPC Pharmaceutical Group Ltd. has entered into an exclusive license agreement with Astrazeneca plc for the global development, manufacture and commercialization of CSPC’s lipoprotein(a) (Lp[a]) inhibitor, YS-2302018, and any pharmaceutical or biological product subsequently developed that includes the compound.
Researchers from Nuvalent Inc. reported preclinical data of NVL-655, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors with IC50 of 0.9 and 1.8 nM against ALK wild-type (WT) and ALK G1202R/L1196M, respectively.
The COVID-19 pandemic pushed the urgency for effective antiviral drugs against coronaviruses. Researchers from Europe conducted machine learning and in vitro validation experiments for the identification of potential antiviral drugs effective against coronaviruses.
Adcencdo ApS has obtained FDA clearance of its IND application for ADCE-D01 in patients with metastatic and/or unresectable soft tissue sarcoma (STS). A first-in-human phase I/II study in patients with metastatic and/or unresectable STS will recruit in the U.S. and Europe.
Kronos Bio Inc. has nominated a development candidate, KB-7898, a p300 lysine acetyltransferase (KAT) inhibitor for the potential treatment of Sjögren’s disease. It is being developed as an orally available therapy for people with Sjögren’s disease, with IND-enabling studies set to begin in the fourth quarter of this year.
RSS
